Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
General Pulmonary
Does rituximab have a potential role in the management of immune checkpoint inhibitor induced pneumonitis?
Related Questions
What strategies are effective for managing cough in patients receiving inhaled treprostinil?
Is the recommended duration of anticoagulation different for provoked DVT compared to provoked PE?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
How would you approach a stable 3 cm iatrogenic pneumothorax in an asymptomatic patient?
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
How do you approach patients who identify so strongly with being sick or with a particular diagnostic label that it makes up a significant portion of their identity?
How do you decide between anticoagulation and observation for an incidentally detected subsegmental pulmonary embolism in elderly patients with a history of gastrointestinal bleeding?
How do you approach dyspnea in a patient with seropositive rheumatoid arthritis with normal imaging findings but abnormal PFT findings (restriction, reduced DLCO)?
Does the presence of a bloody aspirate reduce the diagnostic yield of EBUS bronchoscopy, and if so, what strategies can be employed to minimize its occurrence?
Do you recommend air purifier in bedrooms and office/workplaces of patients with chronic lung disease?
